Best Canadian Cannabis Stocks
Updated March 2026Canadian cannabis companies ranked by market cap. LPs, MSOs listed on TSX/CSE, and other Canadian marijuana stocks.
Canada made history in October 2018 as the first G7 nation to legalize recreational cannabis nationwide, creating a fully regulated market that has attracted global attention and investment. Canadian cannabis stocks include licensed producers, holding companies, and various supporting businesses that were early movers in the legal marijuana industry. The Canadian market also serves as a listing destination for many US MSOs through the Canadian Securities Exchange (CSE).
The Canadian cannabis landscape has evolved considerably since legalization. The initial gold rush mentality that drove valuations to unsustainable levels has given way to a more mature, operationally focused market. Companies that survived the post-legalization shakeout have rationalized costs, improved margins, and in some cases built meaningful international businesses. The Canadian market has also served as a testing ground for product innovation, with sophisticated edible, beverage, and concentrate products launching years ahead of most US markets.
The ranking below includes all Canadian-domiciled cannabis companies sorted by market capitalization. Note that some CSE-listed companies are actually US-operating MSOs that chose Canadian exchanges for their listing — these will appear in the US stocks category rather than here, as we classify by operational headquarters rather than listing exchange.
Best Canadian Cannabis Stocks — Full Rankings
30 stocks · Ranked by market cap
| # | Ticker | Name | Price | Change | Market Cap | Revenue | Margin | P/S | Market Cap |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CRON | Cronos Group | $2.50 | +0.81% | $947.6M | $146.6M | 36.4% | 6.46x | $947.6M |
| 2 | TLRY | Tilray Brands | $6.89 | -1.57% | $802.7M | $837.3M | 26.4% | 0.96x | $802.7M |
| 3 | SNDL | SNDL Inc | $1.51 | -5.03% | $388.8M | $0 | — | — | $388.8M |
| 4 | CGC | Canopy Growth | $1.02 | -2.86% | $385.4M | $278.4M | 28.8% | 1.38x | $385.4M |
| 5 | VFF | Village Farms International | $2.87 | -6.51% | $331.5M | $253.3M | 38.7% | 1.31x | $331.5M |
| 6 | HITI | High Tide Inc | $2.46 | +2.50% | $216.1M | $0 | — | — | $216.1M |
| 7 | ACB | Aurora Cannabis | $3.43 | -3.65% | $194.5M | $0 | — | — | $194.5M |
| 8 | OGI | Organigram Holdings | $1.41 | -2.76% | $190.6M | $0 | — | — | $190.6M |
| 9 | CBWTF | Auxly Cannabis Group | $0.09 | +1.07% | $111.6M | $0 | — | — | $111.6M |
| 10 | LOVFF | Cannara Biotech | $1.30 | -5.09% | $81.9M | $0 | — | — | $81.9M |
| 11 | HEXO | HEXO Corp | $0.71 | +5.62% | $68.9M | $0 | — | — | $68.9M |
| 12 | NVACF | Nova Cannabis | $1.26 | -0.47% | $50.6M | $0 | — | — | $50.6M |
| 13 | DBCCF | Decibel Cannabis Co | $0.09 | +7.20% | $36.1M | $0 | — | — | $36.1M |
| 14 | AVTBF | Avant Brands | $0.52 | +3.82% | $28.6M | $0 | — | — | $28.6M |
| 15 | HMLSF | Global X Marijuana Life Sciences ETF | $5.21 | 0.00% | $26.1M | $0 | — | — | $26.1M |
| 16 | PKANF | Simply Better Brands | $0.21 | 0.00% | $22.2M | $0 | — | — | $22.2M |
| 17 | MEDIF | MediPharm Labs | $0.05 | +1.78% | $19.1M | $0 | — | — | $19.1M |
| 18 | VVIVF | Vivo Cannabis | $0.11 | 0.00% | $17.7M | $0 | — | — | $17.7M |
| 19 | ROMJF | Rubicon Organics | $0.35 | +0.22% | $17.2M | $0 | — | — | $17.2M |
| 20 | GWAYF | Greenway Greenhouse Cannabis | $0.12 | -3.62% | $15.3M | $0 | — | — | $15.3M |
| 21 | MTLNF | MTL Cannabis Corp | $0.39 | 0.00% | $14.3M | $0 | — | — | $14.3M |
| 22 | PCLOF | PharmaCielo | $0.04 | -26.40% | $7.4M | $0 | — | — | $7.4M |
| 23 | OILFF | Nextleaf Solutions | $0.04 | +1.93% | $7.1M | $0 | — | — | $7.1M |
| 24 | DHBUF | Delivra Health Brands | $0.14 | +10.51% | $4.4M | $0 | — | — | $4.4M |
| 25 | NDVAF | Indiva | $0.02 | -10.09% | $4.1M | $0 | — | — | $4.1M |
| 26 | CANN | Trees Corp | $0.03 | +14.29% | $3.5M | $0 | — | — | $3.5M |
| 27 | FFLWF | Fire & Flower Holdings | $0.12 | -31.43% | $3.4M | $0 | — | — | $3.4M |
| 28 | CLCFF | Christina Lake Cannabis | $0.02 | -2.05% | $3.1M | $0 | — | — | $3.1M |
| 29 | DLTNF | Delta 9 Cannabis | $0.01 | -1.95% | $3.0M | $0 | — | — | $3.0M |
| 30 | LFSWF | Lifeist Wellness | $0.03 | +24.48% | $1.1M | $0 | — | — | $1.1M |
Top 3 Spotlight
Cronos Group
Cronos Group ranks #1 in the best canadian cannabis stocks category with a share price of $2.50 and a market capitalization of $947.6M. The company operates in the LP sector and is listed on the NASDAQ. With trailing twelve-month revenue of $146.6M and a gross margin of 36.4%, CRON represents the top-ranked stock in this category based on market cap.
Tilray Brands
Tilray Brands ranks #2 in the best canadian cannabis stocks category with a share price of $6.89 and a market capitalization of $802.7M. The company operates in the LP sector and is listed on the NASDAQ. With trailing twelve-month revenue of $837.3M and a gross margin of 26.4%, TLRY represents the second-ranked stock in this category based on market cap.
SNDL Inc
SNDL Inc ranks #3 in the best canadian cannabis stocks category with a share price of $1.51 and a market capitalization of $388.8M. The company operates in the LP sector and is listed on the NASDAQ. With trailing twelve-month revenue of $0 and a gross margin of N/A, SNDL represents the third-ranked stock in this category based on market cap.
Methodology
Stocks are filtered to include only companies headquartered in Canada and ranked in descending order by market capitalization. Data is sourced from company filings, exchange feeds, and financial data providers. Rankings update automatically as new data becomes available. All financial figures are based on trailing twelve-month (TTM) data unless otherwise noted. The current ranking includes 30 qualifying stocks out of 100 total cannabis companies tracked by Cannabismarketcap.
Key Observations
The top-ranked stock in the best canadian cannabis stocks category is CRON (Cronos Group) with a market cap of $947.6M. The stock trades at $2.50 per share with a market capitalization of $947.6M. In second place is TLRY ($802.7M), followed by SNDL ($388.8M) in third.
Across all 30 qualifying stocks, the average share price is $1.10 and the average market capitalization is $133.5M. The combined trailing twelve-month revenue of all companies in this category is $1.52B. The average gross margin among companies with positive margins is 32.6%. The average price-to-sales ratio is 2.53x.
The most represented sector in this category is LP with 24 out of 30 companies (80%). Among the ranked stocks, 12 are trading higher today while 14 are trading lower. Investors should use these observations as a starting point for further research rather than as the basis for trading decisions.
Investment Considerations
When evaluating stocks in the best canadian cannabis stocks category, consider looking beyond the primary ranking metric to build a holistic view of each company. A stock that ranks well by market cap may have weaknesses in other areas — such as high debt, poor margins, or slowing growth — that the ranking alone does not capture. Cross-reference this list with other Cannabismarketcap category pages and the screener tool to identify stocks that score well across multiple dimensions.
Position sizing is particularly important in cannabis. The sector is inherently volatile, and even the strongest companies can experience 30-50% drawdowns during sector-wide sell-offs triggered by legislative disappointments or broader market risk-off events. Most financial advisors suggest limiting total cannabis exposure to 5-15% of your portfolio, and individual positions to 1-3% depending on your risk tolerance and conviction level.
Dollar-cost averaging (DCA) is a widely recommended approach for building cannabis stock positions over time. Rather than investing your entire allocation at a single price point, spreading purchases across weeks or months can reduce the impact of short-term volatility and lower your average cost basis if prices decline after your initial purchase. This strategy is particularly relevant for the stocks in this category given the sector's history of sharp and sometimes prolonged drawdowns.
Risk Factors
Risk Warning
Canadian cannabis companies face domestic market challenges including oversupply, price compression, persistent illicit market competition, and heavy regulatory compliance costs. Many Canadian companies have experienced significant share price declines from their 2018-2021 peaks and carry legacy cost structures that are difficult to shed. Currency risk affects US investors holding CAD-denominated securities. International expansion strategies, while promising, depend on the pace of regulatory reform in European and other target markets, which has been inconsistent. Some Canadian companies have made large acquisitions that have not generated expected returns, resulting in goodwill impairments and shareholder value destruction.
Compare These Stocks
Head-to-head comparisons between top-ranked stocks in this category.
Frequently Asked Questions
Is cannabis legal in Canada?
Yes, Canada legalized recreational cannabis nationwide on October 17, 2018, through the Cannabis Act. Adults aged 18+ (19+ in some provinces) can legally purchase, possess, and consume cannabis. Licensed producers must obtain authorization from Health Canada to cultivate and sell cannabis, and retail distribution is managed by provincial authorities with a mix of government-run and private retail stores. Medical cannabis has been legal in Canada since 2001, and the regulatory framework for both medical and recreational cannabis continues to evolve.
Which Canadian cannabis stocks trade on US exchanges?
Several major Canadian LPs have dual listings on NASDAQ or NYSE in addition to their primary TSX listings. These include Tilray (TLRY), Canopy Growth (CGC), Aurora Cannabis (ACB), SNDL (SNDL), and Cronos Group (CRON). Dual-listed stocks offer US investors easy access without needing to trade on Canadian exchanges. Smaller Canadian cannabis companies may only trade on the TSX, TSX Venture Exchange, or CSE, requiring a broker that supports Canadian market orders.
How has the Canadian cannabis market performed since legalization?
The Canadian legal cannabis market reached approximately $5-6 billion CAD in annual retail sales by 2025, though this was below early projections of $8-10 billion. The market grew steadily from 2019-2023 but has since plateaued as the initial wave of consumer adoption leveled off. Price compression has been significant, with the average price per gram declining 40-50% from legalization levels. The illicit market still captures an estimated 20-30% of total cannabis sales, particularly in provinces with limited retail access. On the positive side, companies that survived the consolidation phase have improved margins and some are now free cash flow positive.
What international opportunities exist for Canadian cannabis companies?
Germany's partial legalization and growing medical cannabis market represents the largest near-term international opportunity for Canadian LPs. Other key markets include the UK (medical cannabis), Israel (established medical program), Australia (medical and limited recreational), and other EU countries expected to follow Germany's lead. Canadian companies have been building international distribution networks for years and are well-positioned to supply these markets. However, international cannabis revenue still represents a small fraction of total sales for most LPs, and regulatory timelines in target markets remain uncertain.
More on Cannabismarketcap
Disclaimer: The information on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security. Cannabis stocks are highly speculative and carry significant risk of loss, including the potential loss of your entire investment. Past performance is not indicative of future results. The rankings and data presented are based on publicly available financial information and may contain errors or omissions. Always do your own research and consult with a qualified financial advisor before making investment decisions. Cannabismarketcap is not a registered investment advisor, broker-dealer, or financial planner.